How big is Gilead Sciences, Inc.?

As of Jun 18, Gilead Sciences, Inc. has a market capitalization of $134.34 billion, with net sales of $28.69 billion and a net profit of $5.97 billion over the latest four quarters. The company's total assets amount to $58.99 billion, with shareholder's funds of $19.33 billion.

As of Jun 18, Gilead Sciences, Inc. has a market capitalization of 134,344.34 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the company reported net sales of 28,687.00 million for the latest four quarters and a net profit of 5,965.00 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 19,330.00 million and total assets amounting to 58,995.00 million.

What does Gilead Sciences, Inc. do?

Gilead Sciences, Inc. is a large-cap biopharmaceutical company focused on discovering, developing, and commercializing medicines, with a net sales of $6.646 billion and a market cap of approximately $134.34 billion as of March 2025. Key financial metrics include a P/E ratio of 15.00 and a dividend yield of 2.89%.

Overview: <BR>Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines in the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 6,646 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 1,315 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 134,344.34 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Dividend Yield: 2.89% <BR>Debt Equity: 0.83 <BR>Return on Equity: 49.06% <BR>Price to Book: 7.01<BR><BR>Contact Details: <BR>Address: 333 LAKESIDE DR, FOSTER CITY CA: 94404 <BR>Tel: 1 650 5743000 <BR>Fax: 1 650 5789264 <BR>Website: https://www.gilead.com/

Should I buy, sell or hold Gilead Sciences, Inc.?

Who are in the management team of Gilead Sciences, Inc.?

As of March 2022, Gilead Sciences, Inc.'s management team includes Chairman and CEO Daniel O'Day, Lead Independent Director Kevin Lofton, Directors Jeffrey Bluestone, Javier Rodriguez, Anthony Welters, and Independent Director Jacqueline Barton. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Gilead Sciences, Inc. includes the following individuals:<BR><BR>- Mr. Daniel O'Day, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Kevin Lofton, who is the Lead Independent Director.<BR>- Dr. Jeffrey Bluestone, who is a Director.<BR>- Mr. Javier Rodriguez, who is also a Director.<BR>- Mr. Anthony Welters, who serves as a Director.<BR>- Dr. Jacqueline Barton, who is an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Gilead Sciences, Inc. technically bullish or bearish?

As of September 19, 2025, Gilead Sciences, Inc. shows a bullish technical trend with mixed signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the last five years.

As of 19 September 2025, the technical trend for Gilead Sciences, Inc. has changed from mildly bullish to bullish. The weekly MACD is mildly bearish, while the monthly MACD indicates a bullish stance. The daily moving averages are mildly bullish, and the KST shows bullish signals for both weekly and monthly periods. The Bollinger Bands are sideways on the weekly but mildly bullish on the monthly. Overall, the technical indicators suggest a bullish stance, albeit with some caution due to the mixed signals on shorter time frames.<BR><BR>In terms of performance, Gilead has outperformed the S&P 500 year-to-date with a return of 21.78% compared to the S&P's 13.31%, and over the past year, it has returned 34.01% versus the S&P's 16.64%. However, over the 5-year period, Gilead has underperformed the S&P 500, returning 77.43% compared to 100.77%.

Is Gilead Sciences, Inc. overvalued or undervalued?

As of October 17, 2025, Gilead Sciences, Inc. is considered very expensive and overvalued compared to its peers, with a P/E ratio of 15 and stagnant long-term returns, despite a strong year-to-date performance of 32.95%.

As of 17 October 2025, the valuation grade for Gilead Sciences, Inc. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 7.30, and an EV to EBITDA of 11.39. In comparison, Amgen, Inc., a peer in the pharmaceuticals and biotechnology sector, has a higher P/E ratio of 19.10 and a lower EV to EBITDA of 13.08, suggesting that Gilead's valuation may not be justified relative to its competitors.<BR><BR>Gilead's recent stock performance has outpaced the S&P 500, with a year-to-date return of 32.95% compared to the index's 13.30%. However, the company's long-term returns over 10 years show stagnation, with both Gilead and the S&P 500 at 98.08%, which raises concerns about its growth potential despite recent gains. Overall, Gilead Sciences, Inc. is currently overvalued based on its valuation ratios and peer comparisons.